One-step syntheses of nitrofuranyl benzimidazoles that are active against multidrug-resistant bacteria

Journal of Antibiotics

Volumn 64, Issue 10, 2011, Pages 667-671

  Moraski, Garrett C ^a   Thanassi, Jane A ^b   Podos, Steven D ^b   Pucci, Michael J ^b   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b Achillion Pharmaceuticals   (United States)

Author keywords

antibiotic; benzimidazole; MRSA; nitrofuran; VRE

Indexed keywords

2 (5 NITROFURAN 2 YL) 1 H BENZO[D]IMIDAZOLE; 2 (5 NITROFURAN 2 YL) 3H BENZO[D]IMIDAZOLE 4OL; 5 CHLORO 2 (5 NITROFURAN 2 YL) 1H BENZO[D]IMIDAZOLE; 5 FLUORO 2 (5 NITROFURAN 2 YL) 1H BENZO[D]IMIDAZOLE; 7 METHYL 2 (5 NITROFURAN 2 YL) 1H BENZO[D]IMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CIPROFLOXACIN; NITROFURAN DERIVATIVE; NITROFURANYL BENZIMIDAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RNA SYNTHESIS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 80155198766     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.67     Document Type: Article

References (19)

1. Infectious Diseases Society of America. Bad Bugs, No Drugs. http://www.idsociety.org/pa/IDSA-Paper4-final-web.pdf. Infectious Diseases Society of America, Alexandria, VA, 2004.
2. Klevens, R. M. et al. Changes in the epidemiology of methicillin- resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42, 389-391 (2006). (Pubitemid 43122317)
3. Gaynes, R. & Edwards, J. R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41, 848-854 (2005). (Pubitemid 41266753)
4. Fridkin, S. K. et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann. Intern. Med. 135, 175-183 (2001). (Pubitemid 32738311)
5. Jones, R. N. Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 119, 397S-404S (2001).
6. Treitman, A. N., Yarnold, P. R., Warren, J. & Noskin, G. A. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J. Clin. Microbiol. 43, 462-463 (2005). (Pubitemid 40096345)
7. Zhao, G., Miller, M. J., Franzblau, S., Wan, B. & Mö llmann, U. Syntheses and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. Bioorg. Med. Chem. Lett. 16, 5534-5537 (2006). (Pubitemid 44415458)
8. Tangallapally, R. P., Yedapally, R., Lee, R. E., Lenaerts, A. J. M. & Lee, R. E. Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J. Med. Chem. 48, 8261-8269 (2005). (Pubitemid 43032535)
9. Das, B., Metha, A. & Rattan, A. (Ranbaxy Laboratories Limited). Polymorphic forms of phenyl oxazolidinone derivatives. WO 2003/097059, 27 November (2003).
10. Chamberland, S. & Malouin, F. (Ulysses Pharmaceutical Products, Inc.). Halogenated quinazolinyl nitrofurans as antibacterial agents. WO 2005/014585, 17 February (2005).
11. Szarvasi, E. & Fontaine, L. (Lipha, Lyonnaise Industrielle Pharmaceutique). Novel substituted (Nitrofurylacrylidene) hydrazines with antibacterial properties. US 3847911, 7 January (1971).
12. Agarwal, S. K., Akella, S.S.V.S. & Samuel, M. M. (Orchid Chemicals & Pharmaceuticals Ltd.). Oxazolidinone derivatives as antibacterial agents. WO 2003/097640, 27 November (2003).
13. Spazzoni, P. (Sigma-Tau Industrie Farmaceutiche Riuite). Process for preparing nitrofurylbenzimidazole and pharmaceutical compositions having antimycotic, antibacterial and antitubercular activities containing same. EP 0252028A1, 1 January (1988).
14. Chamberland, S. & Malouin, F. (Ulysses Pharmaceutical Products, Inc.). New substituted furan compounds-useful for the treatment of bacterial infection. WO 2006/032138, 30 March (2006).
15. Yonezawa, K., Shibata, H. & Mori, Y. (Toyama Chemical Company Ltd.). Anti-heliobacter agents. WO 1996/008247, 21 March (1996).
16. Magee, A. S. et al. (Essential Therapeutics, Inc.). Novel anti-infective nitrofuran-containing heterocyclic derivatives. WO 2003/000255, 1 March (2003).
17. Pedini, M., Bistocchi, G. A., Ricci, A., Bastianini, L. & Lepri, E. New heterocyclic derivatives of benzimidazole with germicidal activity-XII-Synthesis of N1-glycosyl-2-furyl benzimidazoles. Farmaco 49, 823-827 (1994).
18. McOsker, C. C. & Fitzpatrick, P. M. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J. Antimicrob. Chemother. 33, 23-30 (1994). (Pubitemid 24201981)
19. Mychajlonka, M., McDowell, T. D. & Shockman, G. D. Inhibition of peptidoglycan, ribonucleic acid, and protein synthesis in tolerant strains of Streptococcus mutants. Antimicrob. Agents Chemother. 17, 572-582 (1980). (Pubitemid 10155406)